Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Short term Debt (2016 - 2025)

Historic Short term Debt for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to $5.1 billion.

  • Sanofi's Short term Debt rose 1238.45% to $5.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.1 billion, marking a year-over-year increase of 1238.45%. This contributed to the annual value of $4.9 billion for FY2025, which is 771.24% up from last year.
  • Per Sanofi's latest filing, its Short term Debt stood at $5.1 billion for Q4 2025, which was up 1238.45% from $8.3 billion recorded in Q2 2025.
  • Sanofi's 5-year Short term Debt high stood at $9.9 billion for Q2 2024, and its period low was $2.2 billion during Q4 2023.
  • Moreover, its 5-year median value for Short term Debt was $4.4 billion (2024), whereas its average is $4.9 billion.
  • Its Short term Debt has fluctuated over the past 5 years, first tumbled by 4833.18% in 2023, then skyrocketed by 10441.41% in 2024.
  • Quarter analysis of 5 years shows Sanofi's Short term Debt stood at $3.6 billion in 2021, then increased by 16.95% to $4.3 billion in 2022, then crashed by 48.33% to $2.2 billion in 2023, then skyrocketed by 104.41% to $4.5 billion in 2024, then increased by 12.38% to $5.1 billion in 2025.
  • Its last three reported values are $5.1 billion in Q4 2025, $8.3 billion for Q2 2025, and $4.5 billion during Q4 2024.